Oryzon Genomics (MEX:ORYN) Moat Score: 5/10 (As of Jun. 25, 2026)


MEX:ORYN Oryzon Genomics SA MEX:ORYN
31 GF Score
Price MXN48.59
View Full Analysis

What is Oryzon Genomics Moat Score?

Oryzon Genomics MEX:ORYN 31 Moat Score is 5 as of Jun. 25, 2026. GuruFocus rates MEX:ORYN with a GF Score™ of 31/100. Among 1,405 Biotechnology companies, Oryzon Genomics ranks better than 96.73% on this metric.

Oryzon Genomics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Oryzon Genomics has Narrow Moat: Oryzon Genomics SA benefits from strong R&D capabilities and valuable patents in genomics. While it has some pricing power and innovation, it lacks a dominant market position or significant customer loyalty, resulting in a solid narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Oryzon Genomics might have Narrow Moat - Solid narrow moat.

Oryzon Genomics  (MEX:ORYN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Oryzon Genomics Moat Score Related Terms

MEX:ORYN vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Oryzon Genomics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oryzon Genomics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Moat Score distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Moat Score falls into.


MEX:ORYN
31GF Score
Oryzon Genomics SA MEX:ORYN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Oryzon Genomics (MEX:ORYN) has a Moat Score of 5 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Oryzon Genomics ranks #46 out of 1405 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Oryzon Genomics' Moat Score too high?
Oryzon Genomics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Oryzon Genomics' value of 5 is 150% above this industry median. Based on the distribution chart, Oryzon Genomics ranks #46 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #46 out of 1405 companies for Moat Score. This places Oryzon Genomics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Oryzon Genomics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current Moat Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for MEX:ORYN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.59
Price